Emulate

Boston, United States Founded: 2013 • Age: 13 yrs
Developer of in vitro models for drug development

About Emulate

Emulate is a company based in Boston (United States) founded in 2013 by Daniel Levner.. Emulate has raised $204.49 million across 9 funding rounds from investors including LabCorp, Cedars Sinai and HHS. Emulate offers products and services including Organ-Chip, Software Platform, Consumables, and BioKits. Emulate operates in a competitive market with competitors including CN Bio, AxoSim, Mimetas, Nortis and NETRI, among others.

  • Headquarter Boston, United States
  • Founders Daniel Levner
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $204.49 M (USD)

    in 9 rounds

  • Latest Funding Round
    $82 M (USD), Series E

    Sep 07, 2021

  • Investors
    LabCorp

    & 14 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Emulate

Emulate offers a comprehensive portfolio of products and services, including Organ-Chip, Software Platform, Consumables, and BioKits. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Microfluidic tool for simulating human organ functions in research

Platform for managing and analyzing Organ-Chip experiment data

Materials supporting Organ-Chip operations in laboratory settings

Kits for specific applications like disease modeling

People of Emulate
Headcount 50-200
Employee Profiles 34
Board Members and Advisors 6
Employee Profiles
People
Taehee L.
Product Development Engineer III
People
Max Winkelman
Scientist III
People
Daniel Levner
Co-Founder, CTO & Board Member
People
Jim Corbett
CEO & Board Member

Unlock access to complete

Board Members and Advisors
people
Franklin R. Witney
Board Member
people
Martin Madaus
Executive Chairman
people
Shlomo Melmed
Board Member
people
Eric Moessinger
Board Member

Unlock access to complete

Funding Insights of Emulate

Emulate has successfully raised a total of $204.49M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $82 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Series E — $82.0M
  • First Round

    (28 Jul 2014)

  • Investors Count 15
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2021 Amount Series E - Emulate Valuation Perceptive Advisors , Northpond Ventures
Mar, 2020 Amount Debt – Conventional - Emulate Valuation

investors

Aug, 2019 Amount Series C - Emulate Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Emulate

Emulate has secured backing from 15 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include LabCorp, Cedars Sinai and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Health-tech companies are targeted for venture capital investments.
Founded Year Domain Location
Venture capital firm investing in life sciences & tech sectors
Founded Year Domain Location
Venture capital investments in technology and defense sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Emulate

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Emulate

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Emulate Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Emulate

Emulate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CN Bio, AxoSim, Mimetas, Nortis and NETRI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Organ-on-a-chip platforms are developed for drug discovery applications.
domain founded_year HQ Location
Nerve-on-a-chip technology is advanced by AxoSim for drug development improvement.
domain founded_year HQ Location
Microfluidics-based organ-on-a-chip models for drug evaluation are developed.
domain founded_year HQ Location
Small human tissue segments are generated in microfluidic chips.
domain founded_year HQ Location
Microfluidic devices are developed for industrial applications and brain-on-a-chip models.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Emulate

Frequently Asked Questions about Emulate

When was Emulate founded?

Emulate was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Emulate located?

Emulate is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Is Emulate a funded company?

Emulate is a funded company, having raised a total of $204.49M across 9 funding rounds to date. The company's 1st funding round was a Series C of $27.99M, raised on Jul 28, 2014.

What does Emulate do?

The company was founded in 2013 in Boston, United States, and operates in the biotechnology sector focused on drug development. In vitro models, including organ-chips for the liver, intestine, kidney, and other organs, are developed to simulate human physiology. These models feature tiny channels lined with living human cells and tissues for predicting responses. Culture modules and analytical software applications are also provided to support research operations.

Who are the top competitors of Emulate?

Emulate's top competitors include CN Bio, Cellbox Labs and Nortis.

What products or services does Emulate offer?

Emulate offers Organ-Chip, Software Platform, Consumables, and BioKits.

Who are Emulate's investors?

Emulate has 15 investors. Key investors include LabCorp, Cedars Sinai, HHS, Perceptive Advisors, and ATEL Capital Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available